ArticlePloS one2025
Albumin-corrected anion gap as a predictive marker for mortality in critically Ill cirrhosis patients: an analysis based on the MIMIC-IV database.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Albumin-corrected anion gap and 28-/90-day mortality in cirrhotic patients with invasive fungal infection: a retrospective cohort study.BMC infectious diseases · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe prognostic value of Albumin-Corrected Anion Gap (ACAG) has been extensively examined across a range of diseases; however, its relationship with short- and long-term survival in critically ill cirrhotic patients remains poorly understood. This study aims to investigate and elucidate the association between ACAG levels and mortality risk in this patient population.
methodsInitial analysis involved a univariate assessment of 30-day mortality outcomes, followed by stratification of patient data using X-tile software. Multivariate modeling was employed to identify independent risk factors for mortality. Survival outcomes associated with ACAG levels were analyzed using Kaplan-Meier (K-M) survival curves, while diagnostic accuracy was evaluated through Receiver Operating Characteristic (ROC) curve analysis. Additionally, Restricted Cubic Spline (RCS) regression was utilized to investigate potential non-linear relationships between ACAG levels and mortality risk. Subgroup analyses further validated the interactions between ACAG levels and mortality outcomes in the context of liver cirrhosis.
resultThis study analyzed 2,826 participants, stratifying them into elevated (>20) and normal (≤20) ACAG groups based on X-tile-derived optimal cutoff. Elevated ACAG significantly correlated with higher mortality at 30, 90, 180, and 365 days (P < 0.05). Cox regression confirmed ACAG as an independent mortality predictor, supported by consistent hazard ratios (P < 0.05). K-M analysis revealed worse survival in the elevated ACAG group (P < 0.05). ROC curves indicated fair predictive value for cirrhosis mortality, while RCS analysis showed a linear ACAG mortality relationship. Subgroup analyses revealed no significant interaction effects between ACAG and demographic or clinical variables.
conclusionACAG stands out as a reliable prognostic indicator, showing a meaningful link to mortality rates among critically ill patients with cirrhosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.